Stoke Therapeutics Inc Stock
Price
Target price
€29.20
€29.20
-8.280%
-2.6
-8.280%
€32.49
13.03.26 / Tradegate
WKN: A2PLTL / Symbol: STOK / Name: Stoke Therapeutics / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Stoke Therapeutics Inc Stock
Stoke Therapeutics Inc took a tumble today and lost -€2.600 (-8.280%).
Stoke Therapeutics Inc is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
As a result the target price of 32 € shows a slightly positive potential of 9.59% compared to the current price of 29.2 € for Stoke Therapeutics Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Stoke Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | -8.280% | -1.351% | 7.353% | 281.699% | 7.353% | - | - |
| Personalis Inc | 3.310% | -21.137% | -16.383% | 79.397% | -12.537% | 127.080% | -73.916% |
| Immuron | 3.850% | 8.871% | 28.571% | -55.592% | 0.000% | -59.821% | -87.019% |
Comments
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating and a $60.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat
